A Study to Evaluate ITCA 650 Compared to Glimepiride as Add on Therapy for the Treatment of Type 2 Diabetes

NCT01455922 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: ITCA 650
DRUG: glimepiride

Sponsor

Intarcia Therapeutics